Search

Your search keyword '"Kandioler, D."' showing total 145 results

Search Constraints

Start Over You searched for: Author "Kandioler, D." Remove constraint Author: "Kandioler, D."
145 results on '"Kandioler, D."'

Search Results

12. Functional categories of TP53 mutation in colorectal cancer: results of an International Collaborative Study

13. Abstract

15. TP53 is not a prognostic marker-clinical consequences of a generally disregarded fact

16. Assessing the TP53 marker type in patients treated with or without neoadjuvant chemotherapy for resectable colorectal liver metastases: A p53 Research Group study

20. 369. Assessing the predictive and prognostic value of the biomarker TP53 in patients with resectable colorectal liver metastases treated with and without neoadjuvant fluorouracil based chemotherapy: A p53 research group study

21. Functional categories of TP53 mutation in colorectal cancer : results of an International Collaborative Study

23. A prospective study of the interaction between p53 genotype and overall survival in patients with colorectal cancer liver metastases (CRCLM) with and without neoadjuvant therapy (oxaliplatin and capecitabine/5-FU): A p53 research group study

24. New cellular tools reveal complex epithelial–mesenchymal interactions in hepatocarcinogenesis

37. Molecular genetic differentiation between primary lung cancers and lung metastases of other tumors

40. [Neoadjuvant chemotherapy of patients with breast carcinoma]

42. Different transendothelial migration behaviour pattern of blood monocytes derived from patients with benign and malignant diseases of the breast

44. Survival after surgical treatment of recurrent pulmonary metastases.

47. Standardized intraoperative application of an absorbable polysaccharide hemostatic powder to reduce the incidence of lymphocele after kidney transplantation - a prospective trial.

48. TP53 is not a prognostic marker-clinical consequences of a generally disregarded fact.

49. • Pancho trial (p53-adapted neoadjuvant chemotherapy for resectable esophageal cancer) completed-mutation rate of the marker higher than expected.

50. Stage-directed individualized therapy in esophageal cancer.

Catalog

Books, media, physical & digital resources